Related Experiment Video
Updated: Sep 27, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression
Aruna V Krishnan1, Donna M Peehl, David Feldman
1Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
Abstract:
Prostate cancer (PCa) cells express vitamin D receptors (VDR) and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits the growth of epithelial cells derived from normal, benign prostate hyperplasia, and PCa as well as established PCa cell lines. The growth inhibitory effects of 1,25(OH)(2)D(3) in cell cultures are modulated tissue by the presence and activities of the enzymes 25-hydroxyvitamin D(3) 24-hydroxylase which initiates the inactivation of 1,25(OH)(2)D(3) and 25-hydroxyvitamin D(3) 1alpha-hydroxylase which catalyses its synthesis. In LNCaP human PCa cells 1,25(OH)(2)D(3) exerts antiproliferative activity predominantly by cell cycle arrest through the induction of IGF binding protein-3 (IGFBP-3) expression which in turn increases the levels of the cell cycle inhibitor p21 leading to growth arrest. cDNA microarray analyses of primary prostatic epithelial and PCa cells reveal that 1,25(OH)(2)D(3) regulates many target genes expanding the possible mechanisms of its anticancer activity and raising new potential therapeutic targets. Some of these target genes are involved in growth regulation, protection from oxidative stress, and cell-cell and cell-matrix interactions. A small clinical trial has shown that 1,25(OH)(2)D(3) can slow the rate of prostate specific antigen (PSA) rise in PCa patients demonstrating proof of concept that 1,25(OH)(2)D(3) exhibits therapeutic activity in men with PCa. Further investigation of the role of calcitriol and its analogs for the therapy or chemoprevention of PCa is currently being pursued.
Insights
Vitamin D (1,25(OH)(2)D(3)) inhibits prostate cancer (PCa) cell growth by arresting the cell cycle. Clinical trials show it can slow prostate-specific antigen rise, indicating therapeutic potential for PCa.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Prostate cancer (PCa) cells express vitamin D receptors (VDR).
- 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits the growth of normal, benign, and cancerous prostate epithelial cells.
- Enzymes 25-hydroxyvitamin D(3) 24-hydroxylase and 25-hydroxyvitamin D(3) 1alpha-hydroxylase modulate 1,25(OH)(2)D(3) activity.
Purpose of the Study:
- To investigate the antiproliferative effects of 1,25(OH)(2)D(3) in prostate cancer cells.
- To identify target genes regulated by 1,25(OH)(2)D(3) in prostate cancer.
- To explore the therapeutic potential of 1,25(OH)(2)D(3) in prostate cancer patients.
Main Methods:
- Cell culture experiments with LNCaP human PCa cells.
- cDNA microarray analyses of prostatic epithelial and PCa cells.
- A small clinical trial in PCa patients measuring prostate-specific antigen (PSA) levels.
Main Results:
- 1,25(OH)(2)D(3) induces cell cycle arrest in PCa cells, primarily through IGFBP-3 and p21.
- Microarray analysis revealed numerous 1,25(OH)(2)D(3)-regulated genes involved in growth, oxidative stress, and cell interactions.
- A clinical trial demonstrated that 1,25(OH)(2)D(3) can slow the rate of PSA rise in PCa patients.
Conclusions:
- 1,25(OH)(2)D(3) exhibits antiproliferative activity in prostate cancer via cell cycle arrest and regulation of multiple target genes.
- These findings support the therapeutic potential of calcitriol and its analogs for prostate cancer treatment and chemoprevention.
- Further research is warranted to fully elucidate the role of vitamin D in managing prostate cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Inhibition of CDK Activity
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Abnormal Proliferation

